As of Friday close, Merck & Co. Inc.’s (NYSE:MRK) stock was down -$0.73, moving down -0.69 percent to $105.00. The average number of shares traded per day over the past five days has been 8,205,720 shares. 2 times new highs have been achieved over the past 5 days, with a -$1.34 fall in that time frame. In the last twenty days, the average volume was 7,623,450, while in the previous 50 days, it was 7,849,376.
Since last month, MRK stock retreated -6.04%. Shares of the company fell to $104.51 on 08/04/23, the lowest level in the past month. A 52-week high of $119.65 was reached on 05/03/23 after having rallying from a 52-week low of $84.52. Since the beginning of this year, MRK’s stock price has dropped by -5.36% or -$5.95, and marked a new high 10 times. However, the stock has declined by -12.24% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
MRK stock investors should be aware that Merck & Co. Inc. (MRK) stock had its last reported insider trading activity 2 days ago on Aug 03. MIZELL STEVEN, the EVP, Chief HR Officer of the company, disposed of 4,500 shares for $105.49 on Aug 03. It resulted in a $474,701 divestment by the insider. Romanelli Joseph sold 59 shares at an average price of $107.37 on Aug 02. The insider now owns 0 shares following the transaction. On Aug 02, President, Human Health Int?l Romanelli Joseph sold 30 shares at $107.37 apiece. The transaction was valued at $3,221.
Valuation Metrics
Right now, Merck & Co. Inc. (MRK) has a P/E ratio of about 20.49. The stock’s beta is 0.34. Besides these, the trailing price-to-sales (P/S) ratio of 4.56, the price-to-book (PB) ratio of 5.70, and the price-to-cash flow ratio of 63.68 may also be considered.
The latest dividend of $0.73 per share was paid out, remained unchanged from last year’s $0.73.
Financial Health
In the three months ended June 29, Merck & Co. Inc.’s quick ratio stood at 1.20, while its current ratio was 1.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.60, and the total debt-to-equity ratio was 0.66. On the profitability front, the trailing twelve-month gross margin is 72.80% percent. In the year ended June 29, EBITDA margin amounted to 37.13%, whereas operating margins totaled 28.80%. Based on annual data, MRK earned $41.87 billion in gross profit and brought in $59.28 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 20.90%. Return on equity (ROE) for the past 12 months was 28.90%.
In Merck & Co. Inc.’s quarter-end financial report for June 29, it reported total debt of $28.75 billion against cash and short-term investments of $498.0 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. MRK’s revenue rose 12.74% to $14.96 billion during the quarter, while net income inched up to $13.83 billion. While analysts expected Merck & Co. Inc. to report -$2.18 quarterly earnings, the actual figure was -$2.06 per share, beating the consensus estimate by 5.50%. During the quarter, the company generated $4.8 billion in EBITDA. The liabilities of Merck & Co. Inc. were 60.89 billion at the end of its most recent quarter ended June 29, and its total debt was $30.75 billion. The value of shareholders’ equity is $2.54 billion.
Technical Picture
This quick technical analysis looks at Merck & Co. Inc.’s (MRK) price momentum. With a historical volatility rate of 13.22%, the RSI 9-day stood at 37.04% on 04 August.
With respect to its five-day moving average, the current Merck & Co. Inc. price is down by -1.26% percent or -$1.34. At present, MRK shares trade -3.67% below its 20-day simple moving average and -0.69% percent below its 100-day simple moving average. However, the stock is currently trading approximately -7.30% below its SMA50 and +11.56% above its SMA200.
Stochastic coefficient K was 12.41% and Stochastic coefficient D was 12.56%, while ATR was 2.09. Given the Stochastic reading of 8.03% for the 14-day period, the RSI (14) reading has been calculated as 39.15%. As of today, the MACD Oscillator reading stands at -0.59, while the 14-day reading stands at -1.25.
Analyst Ratings
HSBC Securities launched its rating on Merck & Co. Inc. (NYSE: MRK) to a Hold in a note to investors on July 14, 2023. Merck & Co. Inc. (MRK) has been rated Overweight by analysts. According to 0 brokerage firms, MRK is a sell, and 8 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 5 analysts rate Merck & Co. Inc. stock as buy, with 16 recommending it as overweight.
With a median target price of $126.00, the current consensus forecast for the stock is $110.00 – $135.00. Based on these forecasts, analysts predict Merck & Co. Inc. (MRK) will achieve an average price target of $124.78.
